Drug
Mavenclad
Mavenclad is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
1(20%)
Results Posted
100%(4 trials)
Phase Distribution
Ph phase_4
4
80%
Phase Distribution
0
Early Stage
0
Mid Stage
4
Late Stage
Phase Distribution4 total trials
Phase 4Post-market surveillance
4(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(4)
Detailed Status
Completed4
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 44 (100.0%)
Trials by Status
completed480%
active_not_recruiting120%
Recent Activity
1 active trials
Showing 5 of 5
active_not_recruiting
Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
NCT05797740
completedphase_4
Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)
NCT04783935
completedphase_4
Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)
NCT04776213
completedphase_4
Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)
NCT03369665
completedphase_4
Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)
NCT03364036
Clinical Trials (5)
Showing 5 of 5 trials
NCT05797740
Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
NCT04783935Phase 4
Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension)
NCT04776213Phase 4
Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)
NCT03369665Phase 4
Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)
NCT03364036Phase 4
Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5